IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia ®, Inc., announced today that the first patient to use MammaPrint ® as an enrollment biomarker for the DEBRA Trial is to be enrolled. The Phase III ...

TARPON SPRINGS, Fla., June 2, 2025-- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S.

PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first ...

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif., Oct. 8, 2025 /PRNewswire/ -- Rigel ...

Multicenter Registry Launches to Assess Real-World Outcomes and Clinical Integration of Nonthermal Aliya PEF Ablation REDWOOD CITY, Calif., Aug. 15, 2025 /PRNewswire/ -- Galvanize Therapeutics ...

NES ZIONA, Israel, Nov. 24, 2025 /PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced that the first patient has been ...

RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative ...

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Recross Cardio Inc., a structural heart company pioneering next-generation membrane sealing technology, today announces the first clinical implantation with its ...

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III ...